Epitopea Appoints Klaus Edvardsen M.D., Ph.D. as Chief Medical Officer
Klaus joins Epitopea after serving as Chief Development Officer (CDO) at Nykode Therapeutics, where he oversaw clinical development, regulatory affairs, and project management across oncology, infectious diseases, and autoimmune diseases. Prior to Nykode, he was CDO and CMO at CureVac, where he led development programs spanning oncology, infectious diseases, and rare diseases. He was also Senior Vice President and Head of Global Oncology Development at Merck Healthcare KgaA, where he was accountable for all aspects of early and late-stage development in oncology.
During his four-year tenure at AstraZeneca as Senior Vice President, Head of Global Medicines Development Oncology, Klaus played a pivotal role in the development and regulatory approvals of groundbreaking therapies, including Tagrisso®, Lynparza®, and Calquence®. His leadership was instrumental in securing the fastest FDA and EMA approval for Tagrisso in non-small cell lung cancer and in advancing Lynparza for multiple indications, including ovarian and metastatic breast cancers. Klaus has also driven strategic partnerships, such as the joint development of Lynparza with Merck/MSD.
Earlier in his pharmaceutical industry career, Klaus held senior oncology-focused positions at GSK, Genmab, and Aventis (Sanofi). During his academic career he was a Professor in Experimental Cancer Research at Lund University, Sweden, a Professor in Cell Biology at the University of Bergen, Norway, and an Associate Professor in the Protein Laboratory at the University of Copenhagen, Denmark.
Dr. Klaus Edvardsen, Epitopea's new Chief Medical Officer, commented, 'I am truly honored to join Epitopea at this pivotal time in its journey. The company's pioneering work in leveraging Cryptigens™ as a novel class of tumor-specific antigens offers a unique opportunity to redefine cancer immunotherapy. I look forward to collaborating with Epitopea's talented team to drive the development of transformational therapies that can address significant unmet needs for patients with hard-to-treat cancers.'
Dr. Alan C. Rigby, CEO of Epitopea, said, 'We are thrilled to welcome Klaus to our executive leadership team at such an important stage in Epitopea's growth. Klaus's experience and expertise in oncology drug development and his proven track record of leading innovative therapies from concept to regulatory approval will be instrumental as we advance our pipeline into clinical trials. His leadership undoubtedly strengthens our mission to develop durable, off-the-shelf cancer immunotherapies that can profoundly improve patient outcomes.'
Dr. Edvardsen's appointment comes as Epitopea continues to build on its groundbreaking discoveries of Cryptigens™, a new class of aberrantly expressed tumor-specific antigens uniquely shared across multiple patients with the same tumor type. Using its proprietary CryptoMap™ platform, Epitopea is pioneering the identification and exploitation of these antigens to develop RNA-based immunotherapies targeting cancers with significant unmet medical needs.
The expansion of Epitopea's leadership team and scientific expertise continue to position the company as a trailblazer in the field of RNA-immunotherapy that remains committed to advancing its mission of creating transformative solutions for patients worldwide.
Notes To Editors
Contact InformationEpitopea Dr. Alan C. Rigby – CEOAlan.Rigby@epitopea.com
Scius Communications Katja Stout +44 7789 435990 katja@sciuscommunications.com
Daniel Gooch +44 7747 875479 Daniel@sciuscommunications.com
About EpitopeaEpitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped tumor-specific antigens, which are known as Cryptigen™ TSAs, that are broadly shared across multiple patients with the same tumor type.
The company has created an extensive library of novel Cryptigen™ TSAs, discovered by its proprietary CryptoMap™ platform that leverages immunopeptidomics, genomics, and a bioinformatics pipeline, allowing the identification of aberrantly-expressed, tumor-specific antigens (aeTSA's) that are hidden within cancer's 'junk' DNA. These hidden Cryptigen™ TSAs were first discovered through research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at the Université de Montréal.
Epitopea is backed by leading life science investors including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, Le Fonds de Solidarité FTQ, Investissement Québec, adMare BioInnovations, Jonathan Milner, the Harrington Discovery Institute, IRICoR and Novateur Ventures. To date the company has raised financing of more than USD $45 million. Epitopea was founded in 2021 and consists of sister companies based in Cambridge, UK and in Montreal, Canada. For additional information, please visit www.epitopea.com and follow us on LinkedIn.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
ALT5 Sigma Corporation Appoints Jonathan Hugh as CFO
LAS VEGAS--(BUSINESS WIRE)--ALT5 Sigma Corporation (NASDAQ: ALTS)(FRA: 5AR1) (the 'Company' or 'ALT5'), a fintech and digital asset treasury (DAT) company specializing in turnkey, crypto-related solutions for institutions and merchants, today announced the appointment of industry veteran Jonathan Hugh as CFO of the company. Following ALT5 Sigma's recently announced $1.5 billion financing and the launch of the company's $WLFI Treasury Strategy, we are pleased to announce the appointment of Jonathan Hugh as Chief Financial Officer. His appointment further strengthens the company's leadership team at a pivotal stage in its growth. 'Jonathan is a highly accomplished senior executive with deep international experience across digital assets, commodity trading, and technology,' said Peter Tassiopoulos, CEO of ALT5 Sigma. 'His proven ability to scale high-growth businesses, combined with his expertise in financial strategy and global markets, will be invaluable as we accelerate the global expansion of our Crypto-as-a-Service platform and advance our $WLFI treasury initiatives.' Jonathan brings over 25 years of senior finance and commercial leadership experience in Digital Assets, Technology, Energy, and Commodities Trading, working with both public and private companies ranging from large-cap multinationals to agile high-growth ventures. He previously served as CFO of leading digital asset firms GSR International Ltd, a global market maker, and Zodia Custody Ltd, a regulated institutional custodian. Throughout his career, he has led numerous M&A transactions, executed multiple growth strategies and built robust financial control, compliance and reporting systems to support rapid innovation. Jonathan is a member of the Institute of Chartered Accountants of England and Wales and holds an MA in Law from Cambridge University. His appointment underscores ALT5 Sigma's commitment to attracting world-class leadership talent to drive execution of its strategic vision and deliver long-term value for shareholders. About ALT5 Sigma ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) or (the 'Company') is a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing settlement, payment and safe keeping of digital assets. Since June of 2025, the Company has been a member of the Russell Microcap Growth ®, Russell 3000E ®, and Russell 3000E Growth ® Indexes, as part of the 2025 Russell indexes reconstitution. The Company had previously been included in the Russell Microcap ® Index since June of 2024. The Company recently initiated a $WLFI Treasury Strategy, leveraging a portfolio of digital assets as a strategic component of its balance sheet. This initiative is designed to generate long-term value through disciplined acquisition and deployment of digital assets, while showcasing the Company's capabilities in digital asset payment solutions. The strategy not only strengthens the Company's financial position but also demonstrates the practical, institutional-grade application of its next-generation technology stack in real-world treasury operations. Founded in 2018, the Company provides next-generation blockchain-powered technologies to enable a migration to a new global financial paradigm. The Company, through its subsidiaries, offers two main platforms to its customers: 'ALT5 Pay' and 'ALT5 Prime.' ALT5 Sigma has processed over $6 billion USD in cryptocurrency transactions since inception. ALT5 Pay is an award-winning cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay's checkout widgets and APIs. Merchants have the option to convert to fiat currency(s) automatically or to receive their payment in digital assets. ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named 'ALT5 Pro' that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime's FIX API, as well as through Broadridge Financial Solutions' NYFIX gateway for approved customers. The Company is working on the separation of its biotech business that will move forward under 'Alyea Therapeutics Corporation.' Through its biotech activities, the Company is focused on bringing to market drugs with non-addictive pain-relieving properties to treat conditions that cause chronic or severe pain. The Company's patented product, a novel formulation of low-dose naltrexone (JAN123), is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. The FDA has granted JAN123 Orphan Drug Designation for treatment of CRPS. About World Liberty Financial World Liberty Financial (WLFI) is a pioneering decentralized finance (DeFi) protocol and governance platform dedicated to empowering individuals through transparent, accessible, and secure financial solutions. Inspired by the vision of President Donald J. Trump, WLFI seeks to democratize access to DeFi by creating user-friendly tools that bring the benefits of decentralized finance to a broader audience. WLFI plans to be at the forefront of DeFi, offering an intuitive, robust platform that empowers users to participate actively in the financial future. Forward-Looking Statements This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the expected use of proceeds from the Offerings, the Company's expectation to initiate its $WLFI Treasury Strategy, the profitability and prospective growth of ALT5's platforms and business that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5's services, and technology challenges for future growth or expansion, and statements regarding the Company's potential separation plans of its biotech business. This press release also contains general statements relating to risks that the Company's potential separation plans of its biotech business and the potential for JAN123 to treat CRPS, and other statements, including words such as 'continue', 'expect', 'intend', 'will', 'hope', 'should', 'would', 'may', 'potential', and other similar expressions. Such statements reflect the Company's current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies. This press release also contains statements that are forward-looking in respect of the expected future partial or full disposition of the Company's interests in Alyea without specificity of the scope or methods thereof. Many factors could cause the Company's actual results, performance, or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the 'SEC'). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled 'Risk Factors' in the Company's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
Business Wire
3 hours ago
- Business Wire
Sidus Space Reports Second Quarter 2025 Financial Results and Provides Business Update
CAPE CANAVERAL, Fla.--(BUSINESS WIRE)--Sidus Space (NASDAQ: SIDU), (the 'Company' or 'Sidus'), an innovative space and defense technology company, today announced its financial results for the second quarter ended June 30, 2025, and provided a business update. The Company is scheduled to host a conference call and webcast today, Thursday, August 14, at 5:00 p.m. ET. 'Q2 was about disciplined execution and building durable technology assets. We advanced LizzieSat®‑3 commissioning, fully staffed our 24/7 Mission Operations Center, and expanded our proprietary platform with the Fortis™ VPX Command and Data Handling system and Orlaith™ AI Ecosystem, built to move data and insights seamlessly across space, air, land, and sea,' said Carol Craig, Sidus Chairwoman and CEO. 'We invested ahead of revenue to build core IP and capability. As we enter the second half of the year, we're prioritizing commercialization, aligning spend to milestones, and pursuing capital‑efficient ways to turn our technology into revenue.' Operational Highlights for the Quarter Ending June 30, 2025: Completed commissioning of the ADCS system on LizzieSat®-3 with cutting-edge Autonomous, Machine-Learning-Powered on-board GNC software Fully staffed our in-house Mission Operations Center, enabling 24/7 spacecraft monitoring Received Notice of Allowance for our Modular Satellite Platform—a patent that safeguards the intellectual property behind our adaptable and scalable satellite architecture Deployed Orlaith™ AI system in Asia strengthening global AI and analytics offerings Amended and extended the lunar satellite manufacturing contract with Lonestar Holdings, bringing the total potential value to $120 million Continued building and delivering space and defense hardware for commercial and government customers Subsequent Operational Highlights: Designed LizzieLunar™ to address the Moon's unique operational challenges Successfully executed a capital raise to fund key technology initiatives, including dual-use, multi-domain Fortis™ VPX product line, which supports applications across air, land, sea and space Appointed Tiffany Norwood, Founder and CEO of Tribetan and a globally recognized serial entrepreneur and technology pioneer, to the Board of Directors Financial Highlights for the Second Quarter Ending June 30, 2025: Revenue: $1.3 million, up 36% compared to $928,000 in Q2 2024, reflecting a strategic pivot away from legacy services to new commercial models Cost of Revenue: $2.3 million, up 29% from Q2 2024 due to increased satellite and software depreciation and an increase of material and labor costs Gross Profit (Loss): $(1.0) million, compared to $(841,000) loss in Q2 2024 due to reduced contribution from legacy high-margin services as we transition to higher-value, recurring revenue lines SG&A Expenses: $4.3 million, up from $3.1 million in Q2 2024, driven by headcount growth, launch rescheduling, and operational scaling Adjusted EBITDA: Loss of $3.9 million (non-GAAP), compared to a $3.2 million loss in Q2 2024 Net Loss: $5.6 million, versus $4.1 million in Q2 2024, driven by strategic investment and depreciation Cash Position: $3.6 million as of June 30, 2025, versus $1.4 million a year earlier Conference Call and Webcast Event: Sidus Space Second Quarter Financial Results Conference Call Time: 5:00 p.m. Eastern Time Live Call: + 1-877-269-7751 (U.S. Toll-Free) or +1-201-389-0908 (International) Webcast: For interested individuals unable to join the conference call, a dial-in replay of the call will be available until Thursday, August 28, 2025, at 11:59 P.M. ET and can be accessed by dialing +1-844-512-2921 (U.S. Toll-Free) or +1-412-317-6671 (International) and entering replay pin number: 13755242. An online archive of the webcast will be available for three months following the event at About Sidus Space Sidus Space (NASDAQ: SIDU) is an innovative space and defense technology company offering flexible, cost-effective solutions, including satellite manufacturing and technology integration, AI-driven space-based data solutions, mission planning and management operations, AI/ML products and services, and space and defense hardware manufacturing. With its mission of Space Access Reimagined®, Sidus Space is committed to rapid innovation, adaptable and cost-effective solutions, and the optimization of space system and data collection performance. With demonstrated space heritage, including manufacturing and operating its own satellite and sensor system, LizzieSat®, Sidus Space serves government, defense, intelligence, and commercial companies around the globe. Strategically headquartered on Florida's Space Coast, Sidus Space operates a 35,000-square-foot space manufacturing, assembly, integration, and testing facility and provides easy access to nearby launch facilities. For more information, visit: Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled 'Risk Factors' in Sidus Space's Annual Report on Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Sidus Space, Inc. specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Non-GAAP Measures To provide investors with additional information in connection with our results as determined in accordance with GAAP, we use non-GAAP measures of adjusted EBITDA. We use adjusted EBITDA in order to evaluate our operating performance and make strategic decisions regarding future direction of the company since it provides a meaningful comparison to our peers using similar measures. We define adjusted EBITDA as net income (as determined by U.S. GAAP) adjusted for interest expense, depreciation and amortization expense, acquisition deal costs, severance costs, capital market and advisory fees, equity-based compensation and warrant costs. These non-GAAP measures may be different from non-GAAP measures made by other companies since not all companies will use the same measures. Therefore, these non-GAAP measures should not be considered in isolation or as a substitute for relevant U.S. GAAP measures and should be read in conjunction with information presented on a U.S. GAAP basis. The following table reconciles adjusted EBITDA to net loss (the most comparable GAAP measure) for the three months ended June 30, 2025 and 2024: (i) Sidus Space incurred increased interest expense due to short-term note payable due in Q4 2024 and interest expense related to an asset based loan. (ii) Sidus Space incurred increased depreciation expense 2025 and 2024 with launch and deployment of satellite fixed asset and related satellite software, as well as new ERP software capitalization. (iii) Sidus Space incurred increased equity based compensation expense due to incentive programs implemented by the Board in 2025. Expand SIDUS SPACE, INC. CONSOLIDATED BALANCE SHEETS June 30, December 31, 2025 2024 Assets (Unaudited) Current assets Cash $ 3,634,693 $ 15,703,579 Accounts receivable 873,557 827,886 Accounts receivable - related parties 1,037,606 641,376 Inventory 370,067 255,716 Contract asset 993,504 1,347,386 Contract asset - related party 107,013 46,953 Prepaid and other current assets 4,155,398 3,429,656 Total current assets 11,171,838 22,252,552 Property and equipment, net 17,179,137 14,891,976 Operating lease right-of-use assets 835,140 121,545 Intangible asset 398,135 398,135 Other assets 85,173 81,359 Total Assets $ 29,669,423 $ 37,745,567 Liabilities and Stockholders' Equity Current liabilities Accounts payable and other current liabilities $ 5,755,965 $ 3,388,667 Accounts payable and accrued interest - related party 774,600 673,743 Contract liability - 16,192 Contract liability - related party 107,013 46,953 Asset-based loan liability 7,881,629 6,902,636 Notes payable - 3,059,767 Operating lease liability 260,311 121,544 Total current liabilities 14,779,518 14,209,502 Operating lease liability - non-current 575,598 - Total Liabilities 15,355,116 14,209,502 Commitments and contingencies - - Stockholders' Equity Preferred Stock: 5,000,000 shares authorized; $0.0001 par value; no shares issued and outstanding Series A convertible preferred stock: 2,000 shares authorized; 0 shares issued and outstanding - - Common stock: 210,000,000 authorized; $0.0001 par value Class A common stock: 200,000,000 shares authorized; 18,204,483 and 15,956,816 shares issued and outstanding, respectively 1,821 1,597 Class B common stock: 10,000,000 shares authorized; 100,000 shares issued and outstanding 10 10 Additional paid-in capital 86,705,397 83,887,682 Accumulated deficit (72,392,921 ) (60,353,224 ) Total Stockholders' Equity 14,314,307 23,536,065 Total Liabilities and Stockholders' Equity $ 29,669,423 $ 37,745,567 Expand SIDUS SPACE, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Revenue $ 691,070 $ 834,798 $ 851,774 $ 1,679,909 Revenue - related parties 569,953 92,772 647,743 297,816 Total - revenue 1,261,023 927,570 1,499,517 1,977,725 Cost of revenue 2,288,165 1,768,671 4,155,137 2,734,762 Gross profit (loss) (1,027,142 ) (841,101 ) (2,655,620 ) (757,037 ) Operating expenses Selling, general and administrative expense 4,263,269 3,056,814 8,707,711 6,702,397 Total operating expenses 4,263,269 3,056,814 8,707,711 6,702,397 Net loss from operations (5,290,411 ) (3,897,915 ) (11,363,331 ) (7,459,434 ) Other income (expense) Other income - 1,613 - 1,613 Interest expense (2,546 ) (186,175 ) 22,047 (339,701 ) Interest income 27,979 12,313 94,324 12,313 Asset-based loan expense (360,092 ) (65,920 ) (792,737 ) (161,375 ) Total other income (expense) (334,659 ) (238,169 ) (676,366 ) (487,150 ) Loss before income taxes (5,625,070 ) (4,136,084 ) (12,039,697 ) (7,946,584 ) Provision for income taxes - - - - Net loss (5,625,070 ) (4,136,084 ) (12,039,697 ) (7,946,584 ) Dividend on Series A preferred Stock - - - (42,375 ) Net loss attributed to stockholders $ (5,625,070 ) $ (4,136,084 ) $ (12,039,697 ) $ (7,988,959 ) Basic and diluted loss per common share $ (0.31 ) $ (0.99 ) $ (0.66 ) $ (2.32 ) Basic and diluted weighted average number of common shares outstanding 18,320,025 4,181,344 18,274,485 3,450,577 Expand Six Months Ended June 30, 2025 2024 Cash Flows From Operating Activities: Net loss $ (12,039,697 ) $ (7,946,584 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock based compensation 436,692 160,028 Depreciation and amortization 2,066,969 858,033 Non-cash fees on asset-based loan - Bad debt - - Changes in operating assets and liabilities: Accounts receivable (45,671 ) 553,764 Accounts receivable - related party (396,230 ) (197,355 ) Inventory (114,351 ) (182,757 ) Contract asset 353,882 - Contract asset - related party (60,060 ) (2,827 ) Prepaid expenses and other assets (729,556 ) 946,246 Accounts payable and accrued liabilities 2,537,168 (1,968,107 ) Accounts payable and accrued liabilities - related party 100,857 210,363 Contract liability (16,192 ) - Contract liability - related party 60,060 2,827 Changes in operating lease assets and liabilities 770 (3,699 ) Net Cash provided by (used in) Operating Activities (7,845,359 ) (7,570,068 ) Cash Flows From Investing Activities: Purchase of property and equipment (4,354,130 ) (4,067,741 ) Cash paid for asset acquisition - - Net Cash used in Investing Activities (4,354,130 ) (4,067,741 ) Cash Flows From Financing Activities: Proceeds from issuance of common stock units - 13,742,311 Proceeds from exercise of warrants 2,381,247 - Proceeds from asset-based loan agreement 4,413,239 46,133 Repayment of asset-based loan agreement (3,604,116 ) (1,772,373 ) Repayment of notes payable (3,059,767 ) (150,000 ) Net Cash provided by (used in) Financing Activities 130,603 11,866,071 Net change in cash (12,068,886 ) 228,262 Cash, beginning of period 15,703,579 1,216,107 Cash, end of period $ 3,634,693 $ 1,444,369 Supplemental cash flow information Cash paid for interest $ 630,874 $ 338,116 Cash paid for taxes $ - $ - Non-cash Investing and Financing transactions: Conversion interest and fees of asset based loan $ 169,870 $ - Class A common stock issued for conversion of Series A convertible preferred stock $ - $ 16,566 Recognition of right-of-use asset and lease liability $ 856,787 $ 284,861 Expand
Business Wire
3 hours ago
- Business Wire
Retractable Technologies, Inc. Results for the Periods Ended June 30, 2025
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $10.4 million for the second quarter of 2025 and an operating loss of $5.1 million for the period, as compared to total net sales for the same period last year of $6.0 million and an operating loss of $5.8 million. For the first half of the year, net sales were $18.7 million and operating losses were $9.8 million as compared to 2024 net revenues of $13.6 million and operating losses of $8.7 million. Increased EasyPoint ® needle sales in the first six months of 2025 positively affected overall net revenues, but the lower selling price attributable to the products resulted in a reduction of the total average selling price for the periods presented. Tariffs continue to have a material impact on our results of operation and financial position. The current tariff rate on needles and syringes imported from China is 130% and the rate on other products imported from China is 30%. We spent $2.1 million on tariffs in the first six months of 2025. We are working to lessen the financial impact of tariffs and have shifted to a larger proportion production to our U.S. facility. In the first half of 2025, 38% of our products were manufactured in the U.S. as compared to 9% in the same period of 2024. We implemented reductions in force in the second and third quarters of 2025 to offset the increase in costs from higher domestic manufacturing. Our net loss for the three and six months ended June 30, 2025 was $87 thousand and $10.6 million, respectively. Our net loss for the six months ended June 30, 2025 includes an unrealized net loss on third party debt and equity investments of $5.6 million. We also received a litigation settlement of $1.9 million in the second quarter of 2025. Retractable reports the following results of operations for the three and six months ended June 30, 2025 and 2024, respectively. Further details concerning the results of operations, as well as other matters, are available in Retractable's Form 10-Q filed on August 14, 2025 with the U.S. Securities and Exchange Commission. Comparison of Three Months Ended June 30, 2025 and June 30, 2024 Domestic sales accounted for 81.3% and 83.2% of total revenues for the three months ended June 30, 2025 and 2024, respectively. Domestic revenues increased 69.3%, while domestic unit sales increased 81.8%. Domestic unit sales represented 68.9% of total unit sales for the three months ended June 30, 2025. The increase in unit sales did not translate into a proportional increase in domestic revenues, primarily due to a decrease in average selling price. The average selling price was impacted by product mix and higher transaction fees associated with distributor agreements. The average selling price reduction was significantly impacted by the increase in EasyPoint ® needle sales in relation to all products sold. International revenues for the three months ended June 30, 2025 increased 92.6% compared to the same period in 2024. However, average selling price per unit declined relative to the second quarter of 2024, primarily due to a shift in product mix. International sales for the three months ended June 30, 2025 included Easy Point Needles sold at a discount to certain international customers which reduced the overall average selling price. There remains uncertainty regarding the timing of future international orders. Overall, units sales increased 109.2%. Cost of manufactured product increased 66.1% principally due to an increase in tariffs and additional period costs related to increased domestic production activities. Royalty expense increased 39.4% primarily due to the increase in gross sales, slightly offset by a decrease in royalties payable to a shareholder under a sublicensing agreement. Tariffs are expected to continue to materially increase our costs in future periods. Approximately $561 thousand was spent on tariff expenses in the second quarter of 2025. These costs are included in Cost of manufactured product. Operating expenses decreased 6% primarily due to a decrease in bad debt expense in the second quarter of 2025 as compared to the second quarter of 2024. The loss from operations was $5.1 million compared to a loss of approximately $5.8 million for the same period last year. The decreased loss was due to a decrease in bad debt expense. The unrealized gain on debt and equity securities was $1.6 million due to the increased market values of those securities. We received a settlement payment of $1.9 million in May 2025. The provision for income taxes was $1.8 thousand as compared to a provision for income taxes of $8.3 million for the same period in 2024. The difference is primarily related to fully reserving our deferred tax asset in the second quarter of 2024. Comparison of Six Months Ended June 30, 2025 and June 30, 2024 Domestic sales accounted for 85% and 85.5% of total revenues for the six months ended June 30, 2025 and 2024, respectively. Domestic revenues increased 36.6%, while domestic unit sales increased 47.1%. Domestic unit sales represented 74.9% of total unit sales for the six months ended June 30, 2025. The increase in unit sales did not translate into a proportional increase in domestic revenues, primarily due to a decrease in average selling price. The average selling price was impacted by product mix and higher transaction fees associated with distributor agreements. The average selling price reduction was significantly impacted by the increase in EasyPoint ® needle sales in relation to all products sold. International revenues for the six months ended June 30, 2025 increased 42.8% compared to the same period in 2024. However, average selling price per unit declined relative to the first half of 2024, primarily due to a shift in product mix. International sales for the six months ended June 30, 2025 included Easy Point Needles sold at a discount to certain international customers which reduced the overall average selling price. There remains uncertainty regarding the timing of future international orders. Overall, units sales increased 62.6%. Cost of manufactured product increased 58.8% principally due to increased unit sales, an increase in tariff cost, and additional costs related to an increase in domestic manufacturing expense increased 23.4% primarily due to the increase in gross sales, slightly offset by a decrease in royalties payable to a shareholder under a sublicensing agreement. Tariffs are expected to continue to materially increase our costs in future periods. Approximately $2.1 million was spent on tariff expenses in the first six months of 2025. These costs are included in Cost of manufactured product. Operating expenses decreased 5.2% primarily due to a decrease in bad debt expense and legal and litigation fees. The loss from operations was $9.8 million compared to a loss of approximately $8.7 million for the same period last year. The decreased loss was due to lower operating expenses, but was impacted by lower gross profit. The unrealized loss on debt and equity securities was $5.6 million due to the decreased market values of those securities. We received a settlement payment of $1.9 million in May 2025. The provision for income taxes was $288 thousand as compared to a provision for income taxes of $8.4 million for the same period in 2024. The difference is primarily related to fully reserving our deferred tax asset in the second quarter of 2024. ABOUT RETRACTABLE Retractable manufactures and markets VanishPoint ® and Patient Safe ® safety medical products and the EasyPoint ® needle. The VanishPoint ® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe ® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint ® is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint ® needle also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general line distributors. For more information on Retractable, visit its website at Forward-looking statements in this press release are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect Retractable's current views with respect to future events. Retractable believes that the expectations reflected in such forward-looking statements are accurate. However, Retractable cannot assure you that such expectations will materialize. Actual future performance could differ materially from such statements. Factors that could cause or contribute to such differences include, but are not limited to: tariffs; material changes in demand; Retractable's ability to maintain liquidity; Retractable's maintenance of patent protection; Retractable's ability to maintain favorable third party manufacturing and supplier arrangements and relationships; foreign trade risk; Retractable's ability to access the market; production costs; the impact of larger market players in providing devices to the safety market; and other risks and uncertainties that are detailed from time to time in Retractable's periodic reports filed with the U.S. Securities and Exchange Commission.
